Conexiant’s news site is now MDSpire News. Learn more
Advertisement
Align Prevails in Orthodontic Patent Case
The ruling requires Angelalign to recall and destroy infringing products, pay damages, and cease offering infringing aligner systems incorporating Torque Ridges in 17 European countries.
The article examines the objective, findings, and clinical context described in Align Prevails in Orthodontic Patent Case.
Approach:
Proceedings: Align initiated patent infringement proceedings in August 2025 against companies in the Angelalign group.
Ruling: The UPC’s Paris Local Division found that Angelalign aligner systems incorporating Torque Ridges infringed Align’s European patent relating to Power Ridge technology.
Key Findings:
The court rejected Angelalign’s challenges to the patent’s validity.
The court ordered recall and destruction of infringing products and awarded damages and other relief to Align.
The ruling bars Angelalign from offering infringing Torque Ridges aligners in 17 European countries, including France, Germany, Italy, the Netherlands, and Sweden.
The decision may be appealed.
Interpretation:
Align describes Power Ridge as technology designed to apply targeted forces to improve root torque control and says it remains available through the Invisalign System. Align disputed Angelalign’s characterization of Pressure Points as an upgrade or equivalent replacement for Torque Ridges, but has not publicly stated whether Pressure Points implicates its intellectual property rights.
Limitations:
The ruling may be appealed.
The context does not provide the court’s detailed reasoning or the amount of damages awarded.
Conclusion:
The article also reports other ongoing or appealed disputes between the companies: a UPC injunction concerning ClinCheck Live Update technology; a US International Trade Commission proceeding involving five patents; and an appealed first-instance Chinese judgment concerning Angelalign’s MasterForce and ATreat systems and related aligners.
Antibody-drug conjugates (ADCs) have become an increasingly important part of treatment for several advanced cancers, pairing a tumor-targeting antibody with a cytotoxic payload.
Through its complimentary care program, GSO will provide orthodontic treatment at no cost to up to 100 eligible Georgia residents between the ages of 6 and 21.
